Pharmsynthez Balance Sheet Health
Financial Health criteria checks 1/6
Pharmsynthez has a total shareholder equity of RUB747.0M and total debt of RUB648.8M, which brings its debt-to-equity ratio to 86.9%. Its total assets and total liabilities are RUB1.9B and RUB1.1B respectively.
Key information
86.9%
Debt to equity ratio
₽648.84m
Debt
| Interest coverage ratio | n/a |
| Cash | ₽12.00m |
| Equity | ₽747.02m |
| Total liabilities | ₽1.11b |
| Total assets | ₽1.86b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: LIFE's short term assets (RUB322.0M) do not cover its short term liabilities (RUB1.1B).
Long Term Liabilities: LIFE's short term assets (RUB322.0M) exceed its long term liabilities (RUB50.4M).
Debt to Equity History and Analysis
Debt Level: LIFE's net debt to equity ratio (85.2%) is considered high.
Reducing Debt: LIFE's debt to equity ratio has increased from 22.7% to 86.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if LIFE has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if LIFE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.